WuXi Biologics Reports Record 2025 Annual Results
- Written by PR Newswire
- Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY
- IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps)
- EBITDA rose 38.1% YoY and IFRS net profit increased 45.3% YoY; adjusted EBITDA grew 22.8% YoY and adjusted net profit increased...
Read more: WuXi Biologics Reports Record 2025 Annual Results














